ATXI Stock Overview
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avenue Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$1.25 |
| 52 Week Low | US$0.11 |
| Beta | -0.26 |
| 1 Month Change | -15.88% |
| 3 Month Change | -3.93% |
| 1 Year Change | -87.06% |
| 3 Year Change | -99.81% |
| 5 Year Change | -99.82% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Avenue Therapeutics shares slide on pricing $12M securities offering
Oct 07Avenue Therapeutics up 4% on 1-for-15 reverse stock split
Sep 22Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine
Jun 14We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Mar 19
How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?
Jan 23We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Dec 19Avenue Therapeutics issues regulatory update for IV tramadol
Dec 17Shareholder Returns
| ATXI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.7% | -2.2% | -3.7% |
| 1Y | -87.1% | 11.6% | 20.5% |
Return vs Industry: ATXI underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: ATXI underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ATXI volatility | |
|---|---|
| ATXI Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATXI's share price has been volatile over the past 3 months.
Volatility Over Time: ATXI's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Alix MacLean | www.avenuetx.com |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Avenue Therapeutics, Inc. Fundamentals Summary
| ATXI fundamental statistics | |
|---|---|
| Market cap | US$5.98m |
| Earnings (TTM) | -US$10.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs ATXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATXI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.38m |
| Earnings | -US$10.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATXI perform over the long term?
See historical performance and comparison